Direct-to-Consumer Genetic Testing (DTC-GT)

Definition

Direct-to-consumer genetic testing (DTC-GT) refers to genetic testing marketed and sold directly to individuals, bypassing the traditional clinical gatekeeping model. Consumers self-collect a biological sample (saliva, cheek swab, or blood), send it to a laboratory, and receive a personalised genetic report. DTC-GT encompasses three categories relevant to cardiovascular medicine: monogenic disease risk, polygenic risk scores (PRS), and pharmacogenomics. Despite >33 million DTC-GTs performed in 2022, insufficient evidence supports its routine use in cardiovascular clinical care; however, clinicians increasingly encounter patient-brought DTC-GT results.

Key Concepts

Regulatory Landscape

• DTC-GTs are NOT classified as laboratory-developed tests (LDTs) because they are marketed directly to consumers and are not intended for clinical use — historically exempt from most FDA oversight (sources/consumer-genetictest-aha-2025 — high)
• FDA 2024 rule: Phased oversight increase for LDTs; hybrid/clinician-mediated DTC models (where a clinician is involved) now fall under LDT definition and face greater FDA scrutiny; purely direct-to-consumer tests remain largely unregulated (sources/consumer-genetictest-aha-2025 — high)
• 23andMe is the ONLY DTC company with FDA marketing authorisation — for genetic health risks, carrier screening (Bloom syndrome), pharmacogenomics, and cancer predisposition (BRCA1/BRCA2); these underwent FDA evaluation for accuracy, reliability, and consumer comprehension (sources/consumer-genetictest-aha-2025 — high)
• CMS enforces CLIA standards for analytical validity; FTC and state agencies have additional oversight roles; ACMG has published position statements on DTC-GT quality
• Regulatory gap: Third-party services that download and re-interpret DTC raw genetic data are currently unregulated; DTC companies are NOT covered by HIPAA
• GINA 2008 protects against genetic discrimination in employment and health insurance but does NOT extend to life, disability, or long-term care insurance (sources/consumer-genetictest-aha-2025 — high)

Testing Methodology and Scope

Genotyping (SNP-chip) — Most Common in DTC

• Examines specific variants (SNPs, short indels) rather than determining the entire DNA sequence
• Lower cost; sufficient for PRS computation from large numbers of common variants
• Higher false-negative rate for inherited cardiovascular diseases vs. sequencing — only a selected set of known variants is tested; a novel pathogenic variant will not be detected (sources/consumer-genetictest-aha-2025 — high)
• Curation methods may fall short of clinical-grade standards due to commercial cost pressures; not all variants are reported

Sequencing — Increasingly Available in DTC

• Next-generation sequencing (NGS) determines the nucleotide sequence of individual genes, panels, exome, or whole genome
• Variants classified using ACMG/AMP 5-tier system: pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), likely benign, benign
• Pathogenicity may not be determinable for all variants — especially in non-European populations (underrepresented in reference databases), rare/family-specific variants, or variants in poorly studied genes (sources/consumer-genetictest-aha-2025 — high)

Monogenic Cardiovascular Disease Risk via DTC-GT

• Most heritable CVDs are autosomal dominant with age-dependent penetrance and variable expressivity — making individual risk prediction from DTC results challenging
• Key cardiovascular genes commercially tested (ClinGen definitive/strong evidence):

• All above genes except familial AF genes are listed as ACMG SF v3.2 actionable secondary findings (sources/consumer-genetictest-aha-2025 — high)
• Confirmatory CLIA-certified clinical testing is recommended for ALL health-related monogenic DTC-GT results before any management changes (sources/consumer-genetictest-aha-2025 — high)

Polygenic Risk Scores (PRS) from DTC-GT

• PRS aggregate weighted common SNPs into a score representing relative risk for complex disease (e.g., CAD, AF)
• Established at conception; most predictive earlier in life and for premature events; not affected by treatment changes
• DTC PRS limitations (sources/consumer-genetictest-aha-2025 — high):
  1. No DTC PRS has achieved FDA clearance/approval — clinical validation absent
  2. Array-based genotyping may miss important alleles in certain populations
  3. PRS construction by DTC companies is often opaque, with limited public benchmarking
  4. Ancestry integration is variable — PRS trained primarily in European populations performs poorly in non-European ancestry populations; results may be unreliable
  5. Genetics should not be considered in isolation — integrated risk scores incorporating clinical risk factors are more meaningful
• For clinical-grade cardiovascular PRS considerations, see concepts/ASCVD-Risk-Assessment (sources/consumer-genetictest-aha-2025 — high; sources/lipid-aha-2026 — very high)

Pharmacogenomics via DTC-GT

• 99% of patients carry ≥1 actionable pharmacogenomic variant; DTC pharmacogenomic tests are available over-the-counter in many pharmacies (sources/consumer-genetictest-aha-2025 — high)
• 23andMe pharmacogenomic test (FDA authorized): 33 variants in 8 genes; relevant cardiovascular examples include:
  • CYP2C19 (clopidogrel metabolism — important for antiplatelet response; citalopram dose)
  • SLCO1B1 (statin-induced myopathy risk)
  • CYP2D6, CYP2C9, and others affecting cardiovascular/psychiatric medications
• As of 2020: FDA no longer requires confirmatory clinical testing before acting on 23andMe CYP2C19 results for clopidogrel and citalopram specifically
• Other hybrid DTC companies (Veritas Genetics, Genelex, Pathway Genomics) offer pharmacogenomic testing and now fall under LDT definition
• Third-party services offer to translate DTC raw genetic data into pharmacogenomic reports; these are unregulated
• Clinical guidelines: CPIC (cpicpgx.org) and FDA pharmacogenomic biomarker tables (sources/consumer-genetictest-aha-2025 — high)

ACCE Framework for Evaluating DTC-GT Quality

A 44-question framework assessing test quality across four domains (sources/consumer-genetictest-aha-2025 — high):

• (A) Analytical validity: Technical sensitivity/specificity for accurate genotyping
• (C) Clinical validity: Sensitivity/specificity for the clinical condition; only FDA-authorized DTC-GTs have undergone this evaluation
• (C) Clinical utility: Ability to lead to prevention or better treatment
  • Gene-first FH screening is likely cost-effective in US adults ≤50 years
  • Neonatal HCM gene-first screening may save lives but carries high surveillance costs
  • Evidence for behavioural change from DTC-GT is variable across studies
• (E) Ethical/legal/social: Autonomy and accessibility benefits vs. privacy risks, misinterpretation, insurance discrimination

Clinical Approach to DTC-GT Results

Clinicians confronted with patient-brought DTC-GT results should use a systematic approach (sources/consumer-genetictest-aha-2025 — high):

1. Review the test report — query variants in ClinVar/ClinGen; assess whether DTC company uses ClinGen/ACMG/AMP curation standards; request curation protocol from company if needed
2. Nonactionable results — if no health risk information, low PRS, no relevant pharmacogenomic findings, or negative for monogenic variants without other risk factors: no further follow-up needed in most cases
3. Confirmation of potentially actionable monogenic results — CLIA-certified clinical testing mandatory before management changes; most DTC-GT results positive for pathogenic variants require confirmation
4. Management of actionable results — 3-generation family history; history and physical; condition-specific workup (lipid panel, ECG, exercise test, cardiac imaging); specialist referral
5. Engage genetic counsellors (GCs) — via health system, DTC company telehealth services, or independent telehealth GC companies; GCs cannot diagnose or prescribe but are essential for interpretation
6. Cascade testing — consider for confirmed actionable monogenic findings; no current guidelines exist for cascade screening after DTC-GT; DTC companies do NOT facilitate cascade testing; adoption rate <50% even in traditional genetics workflows

AHA 2023 Framework for Incidentally Identified DTC Variants

• DTC testing bypasses clinician gatekeeping; most DTC tests do NOT undergo FDA review for analytical reliability, clinical validity, or accuracy of clinical claims (sources/incident-gene-aha-2023 — high)
• ACMG has published minimum requirements for DTC-GT, emphasising appropriate pretest counselling and vendor-provided support when LP/P results are returned (sources/incident-gene-aha-2023 — high)
• When a LP/P variant in an ACMG-recommended gene is identified via DTC testing, referral to a centre specialising in inherited CVDs should be considered (sources/incident-gene-aha-2023 — high)
• The Bayesian evaluation framework (pretest clinical probability + variant pathogenicity re-evaluation → posttest probability) applies equally to DTC-identified variants — see concepts/Incidental-Cardiovascular-Variants
• Vendors must not be relied upon for variant interpretation in a clinical context: pathogenicity assertions from DTC companies may differ from clinical laboratory standards and may be outdated (sources/incident-gene-aha-2023 — high)
• DTC-identified VUS variants: case-by-case evaluation in partnership with cardiovascular genetics experts; should NOT trigger cascade testing (sources/incident-gene-aha-2023 — high)

Special Population Considerations

• Athletes: DTC-GT is NOT supported for athletic performance prediction, talent identification, or training optimisation; NCAA-mandated sickle cell trait testing exists but does not validate broader DTC-GT use; significant privacy risks in fitness-genetics integrations (sources/consumer-genetictest-aha-2025 — high)
• Adoptees/limited family history: DTC-GT can provide meaningful genetic information; positive results must be clinically confirmed; genetics professionals should be involved
• Aging populations: Interest in longevity genes (FOXO3, APOE); APOE ε4 has Alzheimer and lipid metabolism implications; high risk of misinterpretation without counselling
• Limited-resource communities: DTC-GT exacerbates equity disparities; insurance will not cover; digital divide compounds barriers; should NOT replace traditional screening (sources/consumer-genetictest-aha-2025 — high)

Contradictions / Open Questions

• DTC-GT insufficient for clinical use yet patients bring results to clinicians: The statement explicitly states "insufficient evidence to support DTC-GT in routine clinical care" but simultaneously provides a clinical algorithm for managing DTC-GT results — reflecting the pragmatic reality that patients will present these results regardless of guideline recommendations. (sources/consumer-genetictest-aha-2025 — high)
• No cascade testing guidelines for DTC-GT: Traditional cascade testing has adoption <50%; DTC-GT introduces additional challenges (no clinical infrastructure, potential misclassified variants leading to family stress/unnecessary procedures). No professional guidelines address cascade screening specifically after DTC-GT results. (sources/consumer-genetictest-aha-2025 — high)
• PRS clinical integration gap: DTC PRSs are untested for clinical validity; physician-ordered PRSs are emerging as LDTs; the boundary between DTC and clinical PRS is dissolving. See concepts/ASCVD-Risk-Assessment for current PRS-in-clinical-care status. (sources/consumer-genetictest-aha-2025 — high; sources/lipid-aha-2026 — very high)
• Population equity in DTC-GT and PRS: Non-European ancestry populations face substantially higher VUS rates and less reliable PRS estimates due to underrepresentation in reference databases and GWAS training populations — DTC-GT may widen rather than narrow genetic health disparities. (sources/consumer-genetictest-aha-2025 — high)
• FH gene-first screening via DTC-GT: Gene-first FH screening is cost-effective in adults ≤50 years, suggesting a role for DTC-GT — yet confirmatory clinical testing is still recommended, complicating the cost-effectiveness argument. (sources/consumer-genetictest-aha-2025 — high; concepts/Familial-Hypercholesterolemia)
• CYP2C19 confirmatory testing no longer required for 23andMe results regarding clopidogrel/citalopram: this creates an inconsistency — FDA has removed the confirmation requirement for these two medications while the broader statement recommends confirmation for all actionable findings. (sources/consumer-genetictest-aha-2025 — high)

Connections

• Related to concepts/Genetic-Testing-in-Cardiomyopathy — clinical-grade cardiomyopathy genetic testing context and comparison
• Related to concepts/Cascade-Family-Screening — cascade testing challenges after DTC-GT
• Related to concepts/Familial-Hypercholesterolemia — gene-first FH screening; LDLR/APOB/PCSK9 DTC testing
• Related to concepts/ASCVD-Risk-Assessment — PRS integration into clinical risk assessment
• Related to concepts/Variant-Reclassification — VUS burden; reclassification implications for DTC results
• Related to concepts/Cardiogenetic-Centers — specialist resource for DTC-GT result interpretation
• Related to entities/HCM — sarcomeric gene DTC panels
• Related to entities/DCM — DCM gene DTC panels
• Related to entities/Long-QT-Syndrome — KCNQ1/KCNH2/SCN5A/CALM DTC panels
• Related to entities/Brugada-Syndrome — SCN5A DTC panels
• Related to entities/ATTR-Amyloidosis — TTR DTC panels; actionable secondary finding
• Related to entities/Anderson-Fabry-Disease — GLA DTC panels; X-linked; actionable
• Related to concepts/Incidental-Cardiovascular-Variants — Bayesian framework for DTC-identified CVD variants
• Related to sources/incident-gene-aha-2023

Sources

• sources/consumer-genetictest-aha-2025
• sources/incident-gene-aha-2023
• sources/lipid-aha-2026